Strategic Wealth Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.1M | Buy |
60,428
+2,231
| +4% | +$495K | 0.91% | 28 |
|
|
2025
Q4 | $13.3M | Buy |
58,197
+5,359
| +10% | +$1.22M | 0.91% | 29 |
|
|
2025
Q3 | $12.2M | Buy |
52,838
+5,168
| +11% | +$1.05M | 0.91% | 27 |
|
|
2025
Q2 | $8.85M | Buy |
+47,670
| New | +$8.86M | 0.7% | 47 |
|
|
2024
Q4 | $8.04M | Buy |
41,550
+4,343
| +12% | +$798K | 0.67% | 51 |
|
|
2024
Q3 | $7.35M | Buy |
37,207
+372
| +1% | +$69.4K | 0.71% | 51 |
|
|
2024
Q2 | $6.32M | Buy |
36,835
+1,201
| +3% | +$199K | 0.66% | 53 |
|
|
2024
Q1 | $6.49M | Buy |
35,634
+2,946
| +9% | +$508K | 0.71% | 44 |
|
|
2023
Q4 | $5.07M | Buy |
32,688
+13,922
| +74% | +$2.03M | 0.62% | 54 |
|
|
2023
Q3 | $2.8M | Buy |
18,766
+853
| +5% | +$125K | 0.37% | 79 |
|
|
2023
Q2 | $2.41M | Buy |
17,913
+694
| +4% | +$102K | 0.31% | 98 |
|
|
2023
Q1 | $2.74M | Buy |
17,219
+1,872
| +12% | +$286K | 0.42% | 69 |
|
|
2022
Q4 | $2.48M | Buy |
15,347
+1,537
| +11% | +$236K | 0.46% | 68 |
|
|
2022
Q3 | $1.85M | Buy |
13,810
+273
| +2% | +$39.2K | 0.39% | 87 |
|
|
2022
Q2 | $2.07M | Sell |
13,537
-3,197
| -19% | -$489K | 0.45% | 81 |
|
|
2022
Q1 | $2.71M | Buy |
16,734
+1,988
| +13% | +$289K | 0.53% | 58 |
|
|
2021
Q4 | $2M | Buy |
14,746
+446
| +3% | +$52.7K | 0.38% | 86 |
|
|
2021
Q3 | $1.54M | Buy |
14,300
+3,286
| +30% | +$375K | 0.45% | 58 |
|
|
2021
Q2 | $1.24M | Sell |
11,014
-409
| -4% | -$46.1K | 0.4% | 66 |
|
|
2021
Q1 | $1.24M | Sell |
11,423
-591
| -5% | -$63.2K | 0.49% | 55 |
|
|
2020
Q4 | $1.29M | Sell |
12,014
-563
| -4% | -$54.1K | 0.54% | 54 |
|
|
2020
Q3 | $1.1M | Sell |
12,577
-2,870
| -19% | -$270K | 0.56% | 55 |
|
|
2020
Q2 | $1.52M | Buy |
15,447
+2,023
| +15% | +$178K | 0.78% | 34 |
|
|
2020
Q1 | $1.19M | Hold |
13,424
| – | – | 0.62% | 47 |
|
|
2019
Q4 | $1.19M | Buy |
13,424
+322
| +2% | +$26.7K | 0.62% | 47 |
|
|
2019
Q3 | $40.3K | Buy |
13,102
+12,130
| +1,248% | +$832K | 0.21% | 92 |
|
|
2019
Q2 | $71K | Buy |
972
+598
| +160% | +$47K | 0.03% | 199 |
|
|
2019
Q1 | $31K | Sell |
374
-57
| -13% | -$4.66K | 0.01% | 290 |
|
|
2018
Q4 | $38K | Sell |
431
-467
| -52% | -$41.1K | 0.02% | 255 |
|
|
2018
Q3 | $85K | Buy |
898
+106
| +13% | +$10.1K | 0.05% | 187 |
|
|
2018
Q2 | $73K | Hold |
792
| – | – | 0.04% | 223 |
|
|
2018
Q1 | $75K | Buy |
792
+400
| +102% | +$43.9K | 0.04% | 212 |
|
|
2017
Q4 | $38K | Buy |
+392
| New | +$36.9K | 0.02% | 242 |
|
Other funds holding ABBV
VCM
VPM
Strategic Wealth Partners's ABBV Position: Q1 2026 in Review
Strategic Wealth Partners increased its AbbVie (ABBV) stake by 3.8% in Q1 2026, buying an estimated $495K and bringing the position to 60,428 shares worth $13.1M. The position accounts for 0.91% of the portfolio, ranked #28.
Strategic Wealth Partners first reported a position in ABBV in Q4 2017 and has held it in 33 quarters since. The position peaked at $13.3M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Strategic Wealth Partners held 60,428 shares of AbbVie worth $13.1M as of Q1 2026.
- Strategic Wealth Partners bought 2,231 AbbVie shares in Q1 2026, an estimated $495K.
- AbbVie made up 0.91% of Strategic Wealth Partners's portfolio in Q1 2026, its #28 holding.
- Strategic Wealth Partners first reported a position in AbbVie in Q4 2017 and has held it in 33 quarters since.
- Strategic Wealth Partners's AbbVie position peaked at $13.3M in Q4 2025.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Strategic Wealth Partners's 13F filing for Q1 2026, filed 12 May 2026.